Thursday, June 11, 2026 — Field Note
A deeper look at one story shaping medical device and health tech.
FIELD NOTE
The Loop Is Closing — and Diabetes Is Showing the Rest of Medtech What That Costs
In New Orleans last weekend, the diabetes-technology field stopped arguing about whose sensor is more accurate and started arguing about something harder: how much of the patient you can remove from the loop entirely.
That was the through-line of the American Diabetes Association’s 86th Scientific Sessions, held June 5–8. Insulet, Dexcom, Medtronic’s MiniMed, Tandem, Beta Bionics, and a clutch of smaller entrants each brought data, but the data all pointed the same direction — toward systems that sense a physiological signal and act on it without a human deciding anything in the moment. Insulet’s STRIVE pivotal trial and EVOLUTION 3 feasibility study were the clearest statement of the thesis: the company’s investigational fully closed-loop system for type 2 diabetes adjusts insulin “with no user settings,” and its EVOLUTION 3 cohort reached 64% time in range from a baseline A1C of 8.1%. MiniMed’s chief product and technology officer told MedTech Dive that, having watched the competition’s results at the meeting, his team is “clearly ahead” in the same race.
The phrase doing the work is fully closed loop — no carb counting, no meal announcements, no dosing math. It is a deliberate step beyond today’s hybrid systems, which still ask the user to tell the device when they’re about to eat. And it is, notably, a product category that does not yet exist commercially. Insulet’s incremental Omnipod 6 — which improved time in range to 77% for type 1 and 76% for type 2 users versus 73% on the current Omnipod 5 — is slated for next year, but its fully closed-loop type 2 system isn’t expected to launch until 2028, with a 510(k) filing planned for 2027. MiniMed is roughly halfway through enrollment in its own pivotal trial. The field is committing capital, trial infrastructure, and public narrative to a category whose proof and reimbursement are still years out.
For readers whose beat isn’t diabetes, that is the part worth sitting with. Diabetes is not a special case here; it is the leading indicator. It arrived at autonomy first because it has the two ingredients that make a closed loop tractable: a single variable you can measure continuously and a single output you can titrate. Once a field has both, the basis of competition migrates predictably — from is the measurement right? to how much of the human can we take out? Any device category approaching sensor maturity is on the same path.
Cardiovascular and neurological device makers are already on it. Earlier this year, Medtronic won FDA approval for BrainSense Adaptive Deep Brain Stimulation, the first closed-loop DBS system, which senses brain signals and adjusts its own therapy without a clinician intervening — and more than 1,000 patients have already received it. A growing body of work in closed-loop autonomic neuromodulation is pushing the same sense-and-respond logic into heart failure and arrhythmia management, building on devices like CVRx’s Barostim. The diabetes field is simply further down a road that cardiology, neurology, and others are now entering.
Which is why the costs diabetes is paying now are the costs those fields should be pricing in. Three travel across every vertical. First, autonomy is a reimbursement and liability problem before it is an engineering problem — the diabetes companies are pre-announcing years ahead of coverage because payers and the FDA have no settled framework for “the device decided.” Second, the hardest moat isn’t the algorithm; it’s trust transfer — persuading a clinician to cede a judgment call they were trained to own. Third, autonomy reshapes the market beyond the original patient. Dexcom’s CONNECT trial, the first Level A evidence for continuous glucose monitoring in type 2 patients not on insulin, posted a 0.9-percentage-point greater A1C reduction than routine care — and in doing so argued that a tool built for the most acute users belongs with a far larger, lower-acuity population. As Fierce Biotech noted, that population is the next battleground.
The open question for the industry is not whether the loop closes. It is whether the evidentiary, regulatory, and trust structures mature fast enough to meet the devices when they arrive. Diabetes is running the experiment in public. Everyone else should be taking notes.
SPONSORED BY RŌG HEALTH
Most medical device companies don't fail on technology. They fail on sequencing.
The most expensive mistakes in Class II and III commercialization happen before launch — raising on a story that doesn’t hold, hiring before positioning is set, going to market before the buyer is clear.
RŌG Health’s Commercial Readiness Check is a free, two-minute assessment that shows you where your commercial readiness is strongest, where you’re most exposed, and which RŌG diagnostic fits where you are.
Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.